Condition: Anxiety · Acute Anxiety · Palliative Care · Sponsor: Insel Gruppe AG, University Hospital Bern
The goal of this double-blind, randomized, placebo-controlled parallel-group multicenter exploratory pilot study (three study arms) is to describe effects and safety of different doses of intranasal midazolam to treat acute anxiety in palliative care patients, while providing pharmacokinetic and pharmacodynamic data.
This description comes directly from the study's public registry record.
Manuel Haschke, MD · +41 (0)31 632 67 93 · manuel.haschke@insel.ch
Ursina Wernli, MSc · ursina.wernli@students.unibe.ch
Always discuss trial participation with your own doctor first.
| Palliativzentrum Bethesda Spital | Basel, Canton of Basel-City, Switzerland | Recruiting |
| Inselspital, Universitätsspital Bern | Bern, Switzerland | Not Yet Recruiting |
| Universitäres Zentrum für Palliative Care (UZP) | Bern, Switzerland | Recruiting |
| Zentrum für Palliative Care, Stadtspital Zürich | Zurich, Switzerland | Recruiting |
| Kompetenzzentrum Palliative Care, Universitätsspital Zürich | Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06330584